BIOADAPTIVES, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)

	June 30, 2018	December 31, 2017
ASSETS		
Current Assets:		
Cash	$ 180,511	$ 360
Marketable securities	4,357	3,203
Prepaid expense and other current assets	21,652	-
Total Current Assets	206,520	3,563
TOTAL ASSETS	**$** 206,520	$ 3,563
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
Current Liabilities:		
Accounts payable and accrued liabilities	30,498	58
Total Current Liabilities	30,498	58
Convertible notes - net of discount of $17,570	298,430	-
Total Liabilities	328,928	58
Stockholders' Equity (Deficit):		
Preferred stock, ($.0001 par value, 5,000,000 shares authorized; none issued and outstanding.)	-	-
Common stock ($.0001 par value, 100,000,000 shares authorized; 15,820,069 and 15,578,262 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively)	1,583	1,559
Additional paid-in capital	3,228,521	3,115,273
Accumulated other comprehensive loss	(57,182)	(58,336)
Accumulated deficit	(3,295,330)	(3,054,991)
Total Stockholders' Equity (Deficit)	(122,408)	3,505
TOTAL LIABILITIES AND STOCKHOLDERS' (EQUITY) DEFICIT	$ 206,520	$ 3,563

The accompanying notes are an integral part of these unaudited consolidated financial statements.

BIOADAPTIVES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	**2017**	**2018**	**2017**
Revenues	$ -	$ -	$ -	$ -
Operating Expenses				
General and administrative	66,147	4,634	68,771	9,358
Professional fees	97,750	58	103,560	218
Stock based compensation	94,515	-	94,515	5,182
Total Operating Expenses	258,412	4,692	266,846	14,758
Other Expense				
Interest expense	(5,493)	-	(5,493)	-
Total Other Expense	(5,493)	-	(5,493)	-
Loss from continuing operation	(263,905)	(4,692)	(272,339)	(14,758)
Gain from discontinued operations	-	617	32,000	1,055
Net Loss	$ (263,905)	$ (4,075)	$ (240,339)	$ (13,703)
Other Comprehensive Income (Loss), net of tax				
Unrealized gain (loss) on marketable securities	1,819	(1,427)	1,154	(1,438)
Other Comprehensive Income (Loss)	1,819	(1,427)	1,154	(1,438)
Comprehensive Loss	(262,086)	(5,502)	(239,185)	(15,141)
Net Loss Per Common Share: Basic and Diluted	$ (0.02)	$ (0.00)	$ (0.01)	$ (0.00)
Net Loss from Continuing Operation Per Common Share: Basic and Diluted	$ (0.02)	$ (0.00)	$ (0.02)	$ (0.00)
Net Income from Discontinued Operations Per Common Share: Basic and Diluted	$ -	$ 0.00	$ 0.00	$ 0.00
Weighted Average Number of Common Shares Outstanding: Basic and Diluted	15,578,262	14,180,456	16,539,638	14,180,456

The accompanying notes are an integral part of these unaudited consolidated financial statements.

BIOADAPTIVES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Six Months Ended June 30, 2018	Six Months Ended June 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss	$ (240,339)	$ (13,703)
Adjustments to reconcile net loss to net cash used in operating activities:		
Stock-based compensation	42,150	-
Stock-based compensation - related party	-	5,182
Warrants issued for service	52,365	-
Gain from discontinued operations	(32,000)	-
Amortization of debt discount	1,187	-
Changes in operating assets and liabilities:		
Inventory	-	1,006
Prepaid expense	(21,652)	-
Accounts payable	30,440	(2,542)
Accrued liabilities – related party	-	9,000
Net Cash Used in Operating Activities	(167,849)	(1,057)
CASH FLOWS FROM INVESTING ACTIVITIES		
Sales of assets	32,000	-
Net cash used in Investing Activities	32,000	-
CASH FLOWS FROM FINANCING ACTIVITIES		
Advances from related party	-	500
Payment on advances from related party	-	(6,561)
Proceeds from Convertible notes	316,000	-
Net Cash Provided By (Used In) Financing Activities	316,000	(6,061)
Net change in cash	180,151	(7,118)
Cash at beginning of period	360	7,635
Cash at end of period	$ 180,511	$ 517
SUPPLEMENTAL CASH FLOW INFORMATION:		
Cash paid for income taxes	$ -	$ -
Cash paid for interest	$ -	$ -
NON-CASH INVESTING AND FINANCING ACTIVITIES		
Unrealized (gain) loss on investments in marketable securities	$ (1,154)	$ 1,438
Common stock issued in conjunction with convertible notes	$ 18,757	$ -

The accompanying notes are an integral part of these unaudited consolidated financial statements.

BioAdaptives, Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Six Months Ended June 30, 2018
(Unaudited)

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business – BioAdaptives, Inc. (formerly known as APEX 8 Inc.) ("BioAdaptives"," Company") was incorporated under the laws of the State of Delaware on April 19, 2013. BioAdaptives is a research, development, and educational company. Our current focus is on products that improve health and wellness. These products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages.

On September 11, 2013, BioAdaptives incorporated Blenders Choice Inc ("Blenders") in Nevada. Blenders is a 100% owned subsidiary and was created as a separate sales and marketing organization. BioAdaptives has elected to manage its sales through independent distributors and has suspended operations of Blenders Choice.

On September 1, 2014, the Company entered into a License Agreement ("Agreement") with Ferris Holding, Inc. ("Ferris"). The Agreement gives the Company the right to use Ferris's proprietary processes and trade secrets, including its stem cell enhancement products. In consideration for these rights, the Company agrees to pay Ferris a fee of 5% of the gross revenue for the products produced and sold by the Company or by way of sub-license pursuant to the rights granted under this Agreement. The initial term of the Agreement is twelve (12) months.

On September 1, 2014, the Company entered into a Sub-License Agreement ("Sub-License") with Essence International, Ltd. ("Essence"). The Sub-License gives Essence the right to use proprietary processes and trade secrets, including its stem cell enhancement products which were obtained by the Company in the Agreement with Ferris. In consideration for the Sub-License, Essence agreed to pay the Company a royalty of 10% of the gross revenue for the products produced and sold by Essence pursuant to the rights granted under this Sub-License. The initial term of the Agreement is twelve (12) months

Basis of presentation – The consolidated financial statements and related disclosures have been prepared by management and are unaudited. The unaudited consolidated financial statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles ("GAAP") of the United States.

2. SUMMARY OF SIGNIFICANT POLICIES

Investment Securities

Equity securities are classified as available for sale and are stated at fair value with unrealized gains and losses excluded from earnings and reported in other comprehensive income, net of tax. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. Realized gains and losses on the sale of investment securities are recognized at the settlement date using the specific identification method and are included in the statements of operations.

In accordance with Accounting Standards Codification ("ASC") 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or in combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Company. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.

Fair value of financial instruments

As required by the Fair Value Measurements and Disclosures Topic of FASB ASC 820-10 (“ASC 820-10”), fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.. The three levels of the fair value hierarchy are as follows:

Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2 Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3 Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Pursuant to ASC 825, Financial Instruments, the fair value of cash and marketable securities is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of cash, marketable securities and, accounts payable, approximate their current fair values because of their nature and respective relatively short maturity dates or durations.

Assets measured at fair value on a recurring basis were presented on the Company’s balance sheet as of June 30, 2018.

Fair Value Measurements as of June 30, 2018 Using:

	Total Carrying Value as of June 30, 2018	Quoted Market Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Equity Securities	$ 4,357	$ 4,357	$ -	$ -
Total	$ 4,357	$ 4,357	$ -	$ -

Equity securities at June 30, 2018, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of $4,357 ($0.0412 per share).

3. GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $3,295,330 as of June 30, 2018. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

4. PREPAID EXPENSE AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets at June 30, 2018 and December 31, 2017 consists of the following:

	June 30, 2018	December 31, 2017
Prepaid rent	$ 11,952	$ -
Other receivable	7,700	
Deposit for rent	2,000	-
	$ 21,652	$ -

5. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities at June 30, 2018 and December 31, 2017 consists of the following;

	June 30, 2018	December 31, 2017
Accounts payable	$ 10,058	$ 58
Accrued interest	4,305	-
Accrued liabilities	16,135	-
	$ 30,498	$ 58

6. CONVETIBLE NOTES

Convertible notes at June 30, 2018 and December 31, 2017 consists of the following:

	June 30, 2018	December 31, 2017
Convertible Notes - originated in April 2018	$ 130,000	$ -
Convertible Notes - originated in June 2018	186,000	-
Total convertible notes payable	316,000	-
Less: Unamortized debt discount	(17,570)	-
Total convertible notes	298,430	-
Less: current portion of convertible notes	-	-
Long-term convertible notes	$ 298,430	$ -

The Company recognized amortization expense related to the debt discount of $1,187 and $0 for the six months ended June 30, 2018 and 2017, respectively, which is included in interest expense in the statements of operation.

For the six ended June 30, 2018 and 2017, the interest expense on convertible notes was $4,305 and $0, respectively. As of June 30, 2018, and December 31, 2017, the accrued interest was $4,305 and $0, respectively.

Convertible Notes – Issued during the six months ended June 30, 2018

During the six months ended June 30, 2018, the Company issued a total principal amount of $316,000 convertible notes for cash proceeds of $316,000. The convertible notes were also provided with a total of 87,000 common shares valued at $18,757. The terms of convertible notes are summarized as follows:

- Term two years;
- Annual interest rates 12%;
- Convertible at the option of the holders at any time after 24 months

- Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price.

7. STOCKHOLDERS' EQUITY

Preferred Stock – The Company is authorized to issue 5,000,000 shares of $.0001 par value preferred stock. As of June 30, 2018, and December 31, 2017, no shares of preferred stock had been issued.

Common Stock – The Company is authorized to issue 100,000,000 shares of $.0001 par value common stock.

During the six months ended June 30, 2018, the Company issued common stock as follows,

- 1,250,000 shares to unrelated party for a subscription receivable of $100,000. On June 30, 2018, the issuance of 1,250,000 shares was cancelled.
- 87,000 shares of common stock, with a value of $18,757, as additional consideration for the issuance of convertible notes (see Note 6)
- 54,807 shares of common stock valued at $14,650 for consulting service
- 100,000 shares of common stock valued at $27,500 based on an employment agreement

As of June 30, 2018, and December 31, 2017, there were 15,820,069 and 15,578,262 shares of the Company's common stock issued and outstanding.

Warrant

During the six months ended June 30, 2018, the Company entered into an agreement with consultant to provide the Company with consulting services in exchange for 2-year warrant to purchase 200,000 shares of common stock with an exercise price of $0.1 per share. The Company recognized warrant of $52,365 as additional paid-in capital.

The fair value of warrant on the date of grant is estimated using the Black Scholes option valuation model. The following assumptions were used for warrant granted during the six months ended June 30, 2018:

	Six months ended June 30, 2018
Expected term	2 years
Expected volatility	274%
Expected dividend yield	-
Risk-free interest rate	2.34%

The following table summarizes information relating to outstanding and exercisable stock options as of June 30, 2018:

Warrants Outstanding			Warrants Exercisable	
Number of Shares	Contractual life (in years)	Exercise Price	Number of Shares	Exercise Price
200,000	1.72	$ 0.10	200,000	$ 0.10

8. DISCONTINUED OPERATIONS

During the six months ended June 30, 2018, the Company sold all rights to the Excel Dogtreat trade mark, research and videos to Ferris Holding, Inc for $32,000 and recorded a gain on the sale of $32,000. The sales of all rights qualified as a discontinued operation of the Company and accordingly, the Company has excluded results of the operations from its Consolidated Statements of Operations to present this business in discontinued operations.

The following table shows the results of operations which are included in the gain from discontinued operations:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	2017	2018	2017
Revenues	$ -	$ 1,201	$ -	$ 2,061
Cost of revenue	-	584	-	1,006
Gross Profit	-	617	-	1,055
Gain on sale of assets	-	-	32,000	-
Gain on discontinued operations	$ -	$ 617	$ 32,000	$ 1,055

9. SUBSEQUENT EVENTS

Subsequent to June 30, 2018, the Company issued convertible notes in the principal amount of $15,000 with 5,000 shares of common stock for cash proceeds of $15,000.